SCHEMBL4047040

SCHEMBL4047040

CSc1nc(-c2ccc(Cl)cc2)cs1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.56
NPC1 O15118 6/20 0.56
LMNA P02545 2/20 0.51
KDM4E B2RXH2 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
MAPT P10636 3/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
ALDH1A1 P00352 2/20 0.51
ALOX15 P16050 1/20 0.51
ALOX12 P18054 1/20 0.51
HSD17B10 Q99714 1/20 0.51
LTA4H P09960 1/20 0.50
PLAU P00749 1/20 0.50
C1S P09871 1/20 0.50
ABL1 P00519 1/20 0.49
CYP19A1 P11511 1/20 0.49
EGFR P00533 1/20 0.48
ALOX5 P09917 3/20 0.46
PTGS2 P35354 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2559834 0.82 RAB9A (0.56) RAB9ANPC1LMNAKDM4ESMN1; SMN2
SCHEMBL11705732 0.82 RAB9A (0.58) RAB9ANPC1LMNAKDM4ESMN1; SMN2
SCHEMBL4047725 0.81 HTR1A (0.58) RAB9ANPC1LMNAKDM4ESMN1; SMN2
SCHEMBL4055990 0.79 NPC1 (0.63) RAB9ANPC1KDM4ESMN1; SMN2MAPT
SCHEMBL4050006 0.79 KDM1A (0.45) RAB9ANPC1KDM4ESMN1; SMN2MAPT
SCHEMBL4050004 0.79 RORC (0.48) RAB9ANPC1LMNAKDM4ESMN1; SMN2
SCHEMBL4050001 0.78 KDM1A (0.44) RAB9ANPC1LMNAMAPTMEN1
SCHEMBL16092893 0.77 HTR1A (0.40) RAB9ANPC1SMN1; SMN2MAPTALDH1A1
SCHEMBL8041816 0.77 RAB9A (0.47) RAB9ANPC1LMNAKDM4ESMN1; SMN2
SCHEMBL11705740 0.76 RAB9A (0.65) RAB9ANPC1LMNAKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247579-A1 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED 2009-10-01 US disclosed
US-20090247579-A1 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED 2009-10-01 US disclosed
US-20090247579-A1 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED 2009-10-01 US disclosed
EP-2029584-A2 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE Cancer Research Technology Limited (GB) 2009-03-04 EP disclosed
WO-2007096618-A2 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-08-30 WO disclosed
US-4022607-A Substituted oxazoles and thiazoles as herbicides SANDOZ, INC. (US) 1977-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247579-A1 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE RB1, RBBP5, RRM2B RAB9A 802/4885NPC1 3790/4885LMNA 1852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.